Generating high quality mRNA-LNP complexes for in vivo delivery: strategies and methods
Thursday, May 29, 2025 - 9:30 IST | 12:00 SGT | 13:00 KST, JST | 14:00 AEST
The production of high-quality mRNA for therapeutic applications presents several challenges, including yield limitation, low capping efficiency, stability concerns, and immunogenicity issues. In fact, crude mRNA preparations can trigger transient inflammatory responses, complicating their use in clinical settings.
In this expert webinar, we will discuss the latest advancements in mRNA synthesis, purification, and delivery technologies that are helping to overcome these barriers. This session will provide a practical walkthrough of using the mMESSAGE mMACHINE T7 mRNA Kit with CleanCap Reagent AG to achieve efficient co-transcriptional capping and generate high-yield, high-purity mRNA with minimal immunogenic contaminants.
You’ll also discover how Vivofectamine delivery solutions are utilized to encapsulate mRNA into lipid nanoparticles (LNPs) for stable and targeted in vivo delivery. We’ll highlight methods to assess the performance, expression, and immunogenic profile of these mRNA-LNP complexes through in vitro and in vivo assays, including luciferase reporter expression in mouse models.
Key learning objectives:
- Learn key steps in mRNA synthesis and purification
- Discover basic concepts and components in the formulation of LNPs
- Gain practical insights and protocols to enhance the efficacy and safety of mRNA-based treatments
Who should attend?
Researchers and professionals involved in mRNA therapeutics or applications.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Speakers
Tyson Vonderfecht holds a PhD in Biochemistry from the University of Colorado, Boulder, and is currently an R&D Staff Scientist in Cell Biology at Thermo Fisher Scientific. Since joining Thermo Fisher in 2019, Tyson has specialized in gene editing and in vitro transcription (IVT) for mRNA synthesis, purification, and applications. He works closely with the Vivofectamine Delivery team to develop mRNA-LNP solutions, enhancing the delivery and efficacy of mRNA. Tyson’s current focus is on developing new mRNA synthesis and purification technologies.
Moderator
